TSHA
Income statement / Annual
Last year (2023), Taysha Gene Therapies, Inc.'s total revenue was $15.45 M,
an increase of 517.55% from the previous year.
In 2023, Taysha Gene Therapies, Inc.'s net income was -$111.57 M.
See Taysha Gene Therapies, Inc.’s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
| Period Ended |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
| Operating Revenue |
$15.45 M
|
$2.50 M
|
$0.00
|
$0.00
|
$0.00
|
| Cost of Revenue |
$1.37 M |
$2.49 M |
$492,000.00 |
$9,000.00 |
$0.00 |
| Gross Profit |
$14.08 M |
$15,000.00 |
-$492,000.00 |
-$9,000.00 |
$0.00 |
| Gross Profit Ratio |
0.91 |
0.01 |
0 |
0 |
0 |
| Research and Development
Expenses |
$56.78 M
|
$91.17 M
|
$131.94 M
|
$31.89 M
|
$987,000.00
|
| General & Administrative
Expenses |
$30.05 M
|
$37.36 M
|
$41.32 M
|
$11.11 M
|
$512,000.00
|
| Selling & Marketing
Expenses |
-$1.37 M
|
$0.00
|
$0.00
|
$0.00
|
-$384,000.00
|
| Selling, General &
Administrative Expenses |
$28.68 M
|
$37.36 M
|
$41.32 M
|
$11.11 M
|
$128,000.00
|
| Other Expenses |
-$1.59 M |
-$18,000.00 |
$0.00 |
-$17.03 M |
$0.00 |
| Operating Expenses |
$85.45 M |
$128.53 M |
$173.27 M |
$43.00 M |
$1.12 M |
| Cost And Expenses |
$86.83 M |
$128.53 M |
$173.27 M |
$43.00 M |
$1.12 M |
| Interest Income |
$3.57 M |
$249,000.00 |
$172,000.00 |
$49,000.00 |
$0.00 |
| Interest Expense |
$5.00 M |
$3.80 M |
$1.43 M |
$28,000.00 |
$0.00 |
| Depreciation &
Amortization |
$1.37 M
|
$2.49 M
|
$492,000.00
|
$9,000.00
|
$4.46 M
|
| EBITDA |
-$70.00 M
|
-$125.80 M
|
-$173.10 M
|
-$59.98 M
|
-$1.12 M
|
| EBITDA Ratio |
-4.53 |
-50.28 |
0 |
0 |
0 |
| Operating Income Ratio
|
-4.62
|
-64.93
|
0
|
0
|
0
|
| Total Other
Income/Expenses Net |
-$40.19 M
|
-$3.57 M
|
-$1.26 M
|
-$17.01 M
|
$0.00
|
| Income Before Tax |
-$111.57 M |
-$166.01 M |
-$174.52 M |
-$60.01 M |
-$1.12 M |
| Income Before Tax Ratio
|
-7.22
|
-66.35
|
0
|
0
|
0
|
| Income Tax Expense |
$1.20 M |
$3.57 M |
$936,000.00 |
-$17.01 M |
-$4.46 M |
| Net Income |
-$111.57 M |
-$169.58 M |
-$175.46 M |
-$43.00 M |
-$1.12 M |
| Net Income Ratio |
-7.22 |
-67.78 |
0 |
0 |
0 |
| EPS |
-0.96 |
-3.86 |
-4.66 |
-2.43 |
-0.0301 |
| EPS Diluted |
-0.96 |
-3.86 |
-4.66 |
-2.43 |
-0.0301 |
| Weighted Average Shares
Out |
$116.12 M
|
$43.95 M
|
$37.65 M
|
$17.67 M
|
$36.99 M
|
| Weighted Average Shares
Out Diluted |
$116.12 M
|
$43.95 M
|
$37.65 M
|
$17.67 M
|
$36.99 M
|
| Link |
|
|
|
|
|
